Clinical Trial Update: The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the impact of certolizumab pegol on MRI-detected synovitis and bone edema in rheumatoid arthritis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

Sponsor: Oklahoma Medical Research Foundation | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED